These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38810843)

  • 1. Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.
    Ferrer F; Tetu P; Dousset L; Lebbe C; Ciccolini J; Combarel D; Meyer N; Paci A; Bouchet S
    Crit Rev Oncol Hematol; 2024 Aug; 200():104385. PubMed ID: 38810843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.
    Fujita KI; Ishida H; Kubota Y; Sasaki Y
    Curr Drug Metab; 2017; 18(3):186-198. PubMed ID: 28059038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
    Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
    Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
    Henriksen JN; Andersen CU; Fristrup N
    Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interactions in patients receiving tyrosine kinase inhibitors.
    Keller KL; Franquiz MJ; Duffy AP; Trovato JA
    J Oncol Pharm Pract; 2018 Mar; 24(2):110-115. PubMed ID: 27941080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases.
    Hulin A; Gelé T; Fenioux C; Kempf E; Sahali D; Tournigand C; Ollero M
    Clin J Am Soc Nephrol; 2024 Jul; 19(7):927-938. PubMed ID: 38079278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of blood levels for oral anticancer drugs].
    van Erp NP; van der Graaf WT
    Ned Tijdschr Geneeskd; 2014; 158():A7884. PubMed ID: 25467023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I.
    Combarel D; Dousset L; Bouchet S; Ferrer F; Tetu P; Lebbe C; Ciccolini J; Meyer N; Paci A
    Crit Rev Oncol Hematol; 2024 Jul; 199():104384. PubMed ID: 38762217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
    Teo YL; Ho HK; Chan A
    Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.
    Wang R; Zhong C; Zhang C; Hua M; Ma D
    Curr Drug Metab; 2017; 18(3):199-206. PubMed ID: 28093990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Molica M; Alimena G
    Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid dysfunctions induced by tyrosine kinase inhibitors.
    Fallahi P; Ferrari SM; Vita R; Di Domenicantonio A; Corrado A; Benvenga S; Antonelli A
    Expert Opin Drug Saf; 2014 Jun; 13(6):723-33. PubMed ID: 24821006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.